



Spring Group Meeting

# San Francisco Specials

APRIL 30 - MAY 2, 2026



Early Therapeutics &  
Rare Cancers Committee

# Early Therapeutics & Rare Cancers Committee

## Leadership

Chair: ..... Razelle Kurzrock, MD  
 Vice-Chair: ..... Young Kwang Chae, MD, MPH  
 Executive Officer: ..... Neeraj Agarwal, MD  
 Statisticians: ..... Megan Othus, PhD  
 ..... Anna B. Moseley, MS  
 ..... Sara Threlkel, BS

## Designates

Data Coordinator: ..... Christine Magner  
 Veterans Affairs: ..... Jimmy Ruiz, MD  
 Oncology Research Professionals: ..... Adam Platt, BS  
 Pharmaceutical Science: ..... Craig Elg, PharmD  
 ..... Sun "Coco" Yang, PharmD, PhD  
 Patient Advocate: ..... TBD  
 Protocol Project Manager: ..... Catrina De Los Santos-Mireles  
 Protocol Project Manager: ..... Erin Rogers, MS (comboMATCH)  
 Clinical Trials Program Manager: ..... Laura Gildner, MS  
 Early Therapeutics Liaisons  
 Breast Committee Liaison: ..... Stephanie L. Graff, MD  
 Cancer Control Liaison: ..... Jason M. Prosek, MD  
 ..... Lara E. Davis, MD (Survivorship)  
 Genitourinary Committee Liaison: ..... Parminder Singh, MD  
 Imaging: ..... TBD  
 Lung Committee Liaison: ..... Shirish M. Gadgeel, MD  
 Lymphoma Committee Liaison: ..... Nasheed Mohammad Hossain, MD  
 Melanoma Committee Liaison: ..... TBD  
 Myeloma Committee Liaison: ..... Frits van Rhee, MD, PhD

## Time/Location

Thursday, April 30, 2026 9:00 a.m. - 11:00 a.m.  
 Room: Seacliff AB (Bay Level)

## Agenda

9:00 - 9:10 am Welcome and Introduction - Razelle Kurzrock, MD  
 9:10 - 9:30 am SN2426, "A Randomized Phase II Study of Amivantamab Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma  
 21CTP.HN01, "CAPT-HN-A Phase II Study of Combined Amivantimab, Carboplatin, and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer - Paul Swiecki, MD

9:30 - 9:50 am CNS Working Group and DART CNS Data - Manmeet Ahluwalia, MD  
 9:50 - 10:10 am S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas" - David Zhen, MD  
 10:10 - 10:30 am Overview of Clinical Outcomes of DART - Sandip Patel, MD  
 10:30 - 10:50 am MD Anderson Cancer Center, NCI CIMAC (Cancer Immune Monitoring and Analysis Centers) Updates on S1609: Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors) - Luisa Maren Solis Soto, MD  
 10:50 - 11:00 am Wrap Up - Razelle Kurzrock, MD

## Active Studies

**SN2426**, "A Randomized Phase II Study of Amivantamab (JNJ-61186372) and hyaluronidase (rHuPH20) versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma." Dr. Swiecicki, Geiger (NRG Study Chair) Activated: 1/28/26.  
**S2012**, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.  
**CTSU/A071401**, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/3/22.  
**CTSU/A092001**, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma." SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.  
**CTSU/AGCT1531**, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." SWOG Champion:

# Early Therapeutics & Rare Cancers Committee

Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 12/17/24.

**CTSU/AOST2031**, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma." SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

**CTSU/AOST2032**, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma." SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23 Temporarily Closed to Accrual as of 9/6/23

**CTSU/HN.11 (CCTG-HN11)**, "SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG." Champion: Dr. Paul Swiecicki. Activated: 9/29/22

## Developing Studies

**S2505**, "Phase III Randomized Study Testing Non-Inferiority of Short-Course Ultra-Fractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) for High-Risk, Resectable Soft Tissue Sarcoma." Dr. Harris

## Closed Studies

**CTSU/A071702**, "A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatic Hyper-mutated Recurrent Glioblastoma." SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23. Closed: 6/2/25.

**CTSU/EA2183**, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20. Closed: 5/23/25:

**CTSU/A071601**, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20. Closed: 5/10/24

**S1609**, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

**CTSU/NRG-GY006**, "A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer." Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

**CTSU/NRG-GY020**, "A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

**NCICOVID**, "NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study." Dr. Karim. Activated: 5/21/20. Closed: 2/1/22.

**CTSU/NRG-GY009**, "A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer." Dr. O'Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/21

**CTSU/NRG-HN007**, "An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

**CTSU/EAY131**, "Molecular Analysis for Therapy Choice (MATCH)." Activated: 8/12/2015. Closed: 12/23/22

**CTSU/NRG-BN007**, "A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma." Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

**CTSU/EA3163**, "Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)." Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

## Proposed Studies

**NRG-BN1803**, "NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas." SWOG Champion: Dr. Ahluwalia.

**NRG-OV1821**, "A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer." Dr. Robinson.

# Early Therapeutics & Rare Cancers Committee

**NRG-BN1855**, "A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Glioblastoma." Dr. M. Ahluwalia.

**NRG-HN1854**, "An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma." Dr. P. Swiecicki.

**NRG-UC1805**, "Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer." Dr. W. Robinson.

## ComboMatch

### Proposed Studies

**EAY191-S9**, "Phase 2 study of Inavolisib in combination with Ribociclib in PIK3CA aberrated Head & Neck + Endometrial cancers." Drs. B. Nelson and J. Rodon.

### Developing Studies

**EAY191-S7**, "A Phase 2 Study Investigating Safety and Efficacy of Trastuzumab Deruxtecan (DS8201/T-DXd) and ATR Inhibitor, Ceralasertib (AZD6738) in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Advanced Solid Tumors." Dr. K. Raghav.

### Closed Studies

**EAY191-S3**, "Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors." Drs. R. Basho and H. Mahdi. Activated: 3/6/23. Closed: 12/18/25.

## Clinical Trials Partnerships (CTP)

### Active Studies

**21CTP.HN01**, CAPT-HN: "A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer." Drs. Swiecicki, Rodriguez, and Brenner. Activation: 9/15/25

## Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

### Published/Accepted Manuscripts

**S1609** A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort. YK Chae, M Othus, S Patel, R Aljumaly, K Win, T Pejovic, S Thomas, W Robinson, H Kim, I Chung, C McLeod, H Chen, E Sharon, H Streicher, C Ryan, C Blanke, R Kurzrock. *Cancer Communications* 2025 Aug;45(8):976-986. <https://pubmed.ncbi.nlm.nih.gov/40402690/>

**S1609** Efficacy and CNS Toxicity of Nivolumab and Ipilimumab in Rare Cancer Brain Metastases: A Multi-Center Basket Trial Analysis (NCI/SWOG S1609). Manmeet S Ahluwalia, Sophie Solomon, Sandip P Patel, Zouina Sarfraz, Megan Othus, Young K Chae, Razelle Kurzrock. *Clin Cancer Res.* 2025 Dec 11. doi: 10.1158/1078-0432.CCR-25-2900. Online ahead of print. <https://pubmed.ncbi.nlm.nih.gov/41378983/>

**S1609** Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609). Megan Othus, Sandip P Patel, Young Kwan Chae, Eliana Dietrich, Manmeet S Ahluwalia, Razelle Kurzrock. *JCO Oncol Adv.* 2025 Nov;2(1):10.1200/oa-25-00110. doi: 10.1200/oa-25-00110. Epub 2025 Nov 24. NIHMS2119227. <https://pubmed.ncbi.nlm.nih.gov/41358143/>

**S1609** Multicenter phase II trial of ipilimumab and nivolumab in metastatic or unresectable perivascular epithelioid cell tumor (PEComa): a substudy of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609 (Cohort 38). Sandip P Patel, Megan Othus, Young K Chae, Tali Azenkot, Michael J Wagner, Sara Threlkel, John H Farley, Christine M Magner, Helen X Chen, Elad Sharon, Christopher W Ryan, Charles Blanke, Razelle Kurzrock. *J Immunother Cancer.* 2025 Oct 20;13(10):e013147. doi: 10.1136/jitc-2025-013147. <https://pubmed.ncbi.nlm.nih.gov/41120126/>

**S1609** Evaluation of mixed response in tumor size and survival in patients with rare cancers treated with dual checkpoint inhibitor therapy (DART SWOG S1609). Young Kwang Chae, Megan Othus, Jiyon Lyu, Seyoung Lee, Seungwon Paik, Eliana Dietrich, Chan Mi Jung, Liam Il-Young Chung, Sandip Patel, Razelle Kurzrock. *Journal*

# Early Therapeutics & Rare Cancers Committee

for *ImmunoTherapy of Cancer* 2026;14:e013260. doi:10.1136/jitc-2025-013260. <https://pubmed.ncbi.nlm.nih.gov/41819545/>

**S1609** DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. Young Kwang Chae, Megan Othus, Sandip P Patel, Floortje J Backes, David M O'Malley, Mihaela Cristea, Aung Naing, Katherine Kurnit, Ramez N Eskander, Scott T Goodrich, William R Robinson, Jennifer Scalici, John Chan, Hussein Ali-Ahmad, John Hays, Colleen McCormick, Edward J Kim, Thanasak Sueblinvong, Amina Ahmed, Jean Siedel, Jessica Thomes Pepin, Justin Neal Bottsford-Miller, Seth Olusegun Fagbemi, Anthony John Jaslowski, Hye Sung Kim, Liam Il-Young Chung, Carolyn Moloney-Lineen, Christine M McLeod, Helen X Chen, Elad Sharon, Howard Streicher, Christopher W Ryan, Charles D Blanke, Razelle Kurzrock. *Journal for the ImmunoTherapy of Cancer* 2026;14:e012805. doi:10.1136/jitc-2025-012805. <https://pubmed.ncbi.nlm.nih.gov/41672597/>

**S1609** Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609). Paul L. Swiecicki, Megan Othus, Sandip P. Patel, Young Kwang-Chae, Razelle Kurzrock. *Cancer*. 2026;e70374. doi:10.1002/cncr.70374. PMC13025072. <https://pubmed.ncbi.nlm.nih.gov/41892875/>

**A091802** Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. Zandberg DP, Allred JB, Rosenberg AJ, Kaczmar JM, Swiecicki P, Julian RA, Poklepovic AS, Bauman JR, Phan MD, Saba NF, Rivera E, Rowland K, Davar D, Cordes J, Ho AL, Zhang M, Berg SA, Munster PN, Schwartz GK. *J Clin Oncol*. 2025 Jul 20;43(21):2398-2408. doi: 10.1200/JCO-25-00759. Epub 2025 May 31. <https://pubmed.ncbi.nlm.nih.gov/40448574/>

**EA3163** Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163. Saba NF, Flamand Y, Lin DT, Chung CH, McDonald MW, Flampouri S, Khan SA, Snyderman CH, Hanna EY, El-Sayed IH, Solares CA, Le CH, Ghaly M, Hwang PH, Shin DM, Axelrod RS, Ikpeazu CV, Adkins DR, Duan F, Cohen M, Samuels MA, Swiecicki PL, Subramaniam RM, Chakravarthy AB, Burtness BA. *Clin Cancer Res*. 2025 Jun 13;31(12):2339-2346. doi: 10.1158/1078-0432.CCR-24-4085. <https://pubmed.ncbi.nlm.nih.gov/40227186/>

**EAY131** Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H. Mohamed A Gouda, Zihan Wei, Jordi Rodon, Michael A Davies, Filip Janku, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Rubinstein,

David R Patton, P Mickey Williams, Stanley R Hamilton, Raymond Liu, Daniela A Bota, Paul L Swiecicki, Gary L Buchschacher, James V Tricoli, Barbara A Conley, Carlos L Arteaga, Lyndsay N Harris, Peter J O'Dwyer, Alice P Chen, Keith T Flaherty. *JCO Precis Oncol*. 2025 Feb;9:e2400451. doi: 10.1200/PO-24-00451. Epub 2025 Feb 6. NIHMS2058197. <https://pubmed.ncbi.nlm.nih.gov/39913886/>

**EAY131** Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131). Mohamed A Gouda, Filip Janku, Ying Yuan, Leylah M Drusbosky, Alice P Chen, Xiaofeng Zheng, Keyur Patel, Stanley R Hamilton, Mark Routbort, James V Tricoli, P Mickey Williams, A John Iafrate, Jeffrey Sklar, Brent Coffey, Richard F Little, Carlos L Arteaga, Peter J O'Dwyer, Keith T Flaherty, Lyndsay N Harris, Funda Meric-Bernstam. *Clin Cancer Res*. 2025 Oct 15;31(20):4299-4310. doi: 10.1158/1078-0432.CCR-24-3531. NIHMS2084882. <https://pubmed.ncbi.nlm.nih.gov/40388547/>

## Submitted Manuscripts

**S1609** Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Lung and/or Liver Metastases (NCI/SWOG S1609). Y Wang, M Othus, YK Chae, M Davies, E Dietrich, SP Patel, R Kurzrock. Submitted 2026.

**S1609** Outcomes of Patients with Rare Adenocarcinoma versus Squamous Cell Carcinomas Treated with Nivolumab plus Ipilimumab (NCI/SWOG S1609: DART trial). Megan Othus, Nolan Cole, Helen Omega, Young Kwan Chae, Sandip P Patel, Razelle Kurzrock. Submitted 2026.

## Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	EAY191-S3	S2012	A071401	AGCT1531	EAY191	EAY191A3	EAY191A6	EAY191E4
Baylor College of Medicine/Duncan Comp Cancer Center	-	1	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	1	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	2	-	-	-	-	-	-
Carolinas Medical Center/Levine Cancer Institute	-	5	-	-	-	-	-	-
Cedars-Sinai Medical Center	2	-	-	-	5	-	-	-
CommonSpirit Health Research Institute	-	1	1	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	1	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	16	-	-	-	-	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	1	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	1	-	-	1	-	1	-
Heartland Cancer Research NCORP	-	1	-	-	-	-	-	-
Henry Ford Hospital	-	2	1	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	6	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	4	-	-	-	-	-	-
Moffitt Cancer Center	-	9	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	1	-	-	-	-
Northwestern University LAPS	-	5	1	-	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	10	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	1	1	-	-	-	-	-	-
Regents of the University of Michigan	-	2	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	1	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	1	-	4	-	1	3
UC San Diego Moores Cancer Center	-	-	2	2	1	-	-	-
University of Colorado Cancer Center LAPS	-	-	1	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	-	-	-	10	2	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	2	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	10	2	-	-	-	-	-
ALLIANCE	6	21	-	-	-	-	-	-
ECOG-ACRIN	9	14	-	-	-	-	-	-
NRG	10	10	-	-	-	-	-	-
<b>Total</b>	<b>33</b>	<b>133</b>	<b>9</b>	<b>4</b>	<b>21</b>	<b>2</b>	<b>2</b>	<b>3</b>

